检索结果 - Daniel Afar

Refine Results
  1. 1
    The Dimerization Property of Glutathione -Transferase Partially Reactivates Bcr-Abl Lacking the Oligomerization Domain

    The Dimerization Property of Glutathione -Transferase Partially Reactivates Bcr-Abl Lacking the Oligomerization Domain 由 Yoshiro Maru, Daniel Afar, Owen N. Witte, Masabumi Shibuya

    出版 1996
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene

    Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene 由 Andrei Goga, Jami McLaughlin, Daniel Afar, Douglas C. Saffran, Owen N. Witte

    出版 1995
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Signaling by ABL oncogenes through cyclin D1.

    Signaling by ABL oncogenes through cyclin D1. 由 Daniel Afar, J McLaughlin, Charles J. Sherr, Owen N. Witte, Martine F. Roussel

    出版 1995
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Regulation of Btk by Src Family Tyrosine Kinases

    Regulation of Btk by Src Family Tyrosine Kinases 由 Daniel Afar, Hyunsun Park, Brian W. Howell, David J. Rawlings, Jonathan A. Cooper, Owen N. Witte

    出版 1996
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    STY, a tyrosine-phosphorylating enzyme with sequence homology to serine/threonine kinases.

    STY, a tyrosine-phosphorylating enzyme with sequence homology to serine/threonine kinases. 由 Brian W. Howell, Daniel Afar, John I. Lew, Elizabeth Douville, Pamela L. Icely, Douglas A. Gray, John C. Bell

    出版 1991
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Regulation of the Oncogenic Activity of BCR-ABL by a Tightly Bound Substrate Protein RIN1

    Regulation of the Oncogenic Activity of BCR-ABL by a Tightly Bound Substrate Protein RIN1 由 Daniel Afar, Limin Han, Jami McLaughlin, Stephane Wong, Ajay Dhaka, Kalindi Parmar, Naomi Rosenberg, Owen N. Witte, John Colicelli

    出版 1997
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    A Point Mutation in the SH2 Domain of Bruton's Tyrosine Kinase in Atypical X-Linked Agammaglobulinemia

    A Point Mutation in the SH2 Domain of Bruton's Tyrosine Kinase in Atypical X-Linked Agammaglobulinemia 由 Douglas C. Saffran, Ornella Parolini, M.E. Fitch-Hilgenberg, David J. Rawlings, Daniel Afar, Owen N. Witte, Mary Ellen Conley

    出版 1994
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Protein binding and signaling properties of RIN1 suggest a unique effector function

    Protein binding and signaling properties of RIN1 suggest a unique effector function 由 Limin Han, Derrick Wong, Ajay Dhaka, Daniel Afar, Michael A. White, Wielin Xie, Harvey R. Herschman, Owen N. Witte, John Colicelli

    出版 1997
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

    A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma 由 Jeffrey A. Zonder, Ann Mohrbacher, Seema Singhal, Frits van Rhee, William Bensinger, Han Ting Ding, John Fry, Daniel Afar, Anil Singhal

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Transcriptional activation of a ras-like gene (kir) by oncogenic tyrosine kinases.

    Transcriptional activation of a ras-like gene (kir) by oncogenic tyrosine kinases. 由 Lucie Cohen, Randolph N. Mohr, Y Y Chen, Mary Huang, R. Kato, Dominique Dorin, Fuyuhiko Tamanoi, Andrei Goga, Daniel Afar, Naomi Rosenberg

    出版 1994
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Regulation of Btk Function by a Major Autophosphorylation Site Within the SH3 Domain

    Regulation of Btk Function by a Major Autophosphorylation Site Within the SH3 Domain 由 Hyunsun Park, Matthew I. Wahl, Daniel Afar, Christoph W. Turck, David J. Rawlings, Christina Tam, Andrew M. Scharenberg, Jean‐Pierre Kinet, Owen N. Witte

    出版 1996
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

    Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma 由 Andrzej Jakubowiak, Don M. Benson, William Bensinger, David S. Siegel, Todd M. Zimmerman, Ann Mohrbacher, Paul G. Richardson, Daniel Afar, Anil Singhal, Kenneth C. Anderson

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Oligomerization of the ABL Tyrosine Kinase by the Ets Protein TEL in Human Leukemia

    Oligomerization of the ABL Tyrosine Kinase by the Ets Protein TEL in Human Leukemia 由 Todd R. Golub, Andrei Goga, George F. Barker, Daniel Afar, Jami McLaughlin, Stefan K. Bohlander, Janet D. Rowley, Owen N. Witte, D. Gary Gilliland

    出版 1996
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Epithelial membrane protein-1 is a biomarker of gefitinib resistance

    Epithelial membrane protein-1 is a biomarker of gefitinib resistance 由 Anjali Jain, Charles Tindell, Isett Laux, Jacob B. Hunter, John A. Curran, Anna Galkin, Daniel Afar, Nina Aronson, Steven Shak, Ronald B. Natale, David B. Agus

    出版 2005
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors

    STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors 由 René Hubert, Igor Vivanco, Emily Chen, Shiva Rastegar, Kahan Leong, S.C. Mitchell, Rashida Madraswala, Yanhong Zhou, James Kuo, Arthur Raitano, Aya Jakobovits, Douglas C. Saffran, Daniel Afar

    出版 1999
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors

    First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors 由 John H. Strickler, Colin D. Weekes, John Nemunaitis, Ramesh K. Ramanathan, Rebecca S. Heist, Daniel Morgensztern, Eric Angevin, Todd M. Bauer, Huibin Yue, Monica Motwani, Apurvasena Parikh, Edward B. Reilly, Daniel Afar, Louie Naumovski, Karen Kelly

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf–mediated interactions with bone marrow stromal cells

    CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf–mediated interactions with bone marrow stromal cells 由 Yu‐Tzu Tai, Ender Soydan, Weihua Song, Mariateresa Fulciniti, Kihyun Kım, Fangxin Hong, Xian-Feng Li, Peter Burger, Matthew Rumizen, Sabikun Nahar, Klaus Podar, Teru Hideshima, Nikhil C. Munshi, Giovanni Tonon, Ruben D. Carrasco, Daniel Afar, Kenneth C. Anderson

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

    Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma 由 Frits van Rhee, Susann Szmania, Myles Dillon, Anne M. van Abbema, Xin Li, Mary K. Stone, Tarun K. Garg, Jumei Shi, Amberly Moreno-Bost, Rui Yun, Balaji Balasa, Bishwa Ganguly, Debra T. Chao, Audie Rice, Fenghuang Zhan, John D. Shaughnessy, Bart Barlogie, Shmuel Yaccoby, Daniel Afar

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

    Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu 由 Yu‐Tzu Tai, Myles Dillon, Weihua Song, Merav Leiba, Xian-Feng Li, Peter Burger, Alfred Ian Lee, Klaus Podar, Teru Hideshima, Audie Rice, Anne van Abbema, Lynne Jesaitis, Ingrid W. Caras, Debbie A. Law, Edie Weller, Wanling Xie, Paul G. Richardson, Nikhil C. Munshi, Claire Mathiot, Hervé Avet‐Loiseau, Daniel Afar, Kenneth C. Anderson

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Preclinical validation of anti-TMEFF2-auristatin E–conjugated antibodies in the treatment of prostate cancer

    Preclinical validation of anti-TMEFF2-auristatin E–conjugated antibodies in the treatment of prostate cancer 由 Daniel Afar, Vinay Bhaskar, Eric Ibsen, Danna Breinberg, Susan M. Henshall, James G. Kench, Marija Drobnjak, Rick Powers, Melanie Wong, Ferdinand Evangelista, Chris O’hara, David B. Powers, Robert B. DuBridge, Ingrid W. Caras, Ruth Winter, Terri Anderson, Nanette Solvason, Phillip D. Stricker, Carlos Cordón-Cardo, Howard I. Scher, John J. Grygiel, Robert L. Sutherland, Richard Murray, Vanitha Ramakrishnan, Debbie A. Law

    出版 2004
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: